Prashant R Murumkar

List of Publications by Year in Descending Order

52 papers	1,051 citations	20 h-index	31 g-index
58 ext. papers	1,225 ext. citations	4 avg, IF	4.37 L-index

#	Paper	IF	Citations
52	Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting β-catenin/TCF4 signaling pathway.. *Translational Oncology*, **2022**, 19, 101395	4.9	
51	Further Studies on Cationic Gemini Amphiphiles as Carriers for Gene Delivery-The Effect of Linkers in the Structure and Other Factors Affecting the Transfection Efficacy of These Amphiphiles.. *ACS Omega*, **2021**, 6, 33370-33388	3.9	0
50	Design and synthesis of novel N-[3-(benzimidazol-2-ylamino)phenyl]amine and N-[3-(benzoxazol-2-ylamino)phenyl]amine derivatives as potential anticancer agents. *Molecular Diversity*, **2021**, 1	3.1	1
49	Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy. *Archives of Biochemistry and Biophysics*, **2021**, 710, 108995	4.1	1
48	Development of Steroidal Aromatase Inhibitors as Potential Anti-breast Cancer Agents. *Current Enzyme Inhibition*, **2020**, 16, 45-62	0.5	1
47	New pyrazolyl-dibenzo[b,e][1,4]diazepinones: room temperature one-pot synthesis and biological evaluation. *Molecular Diversity*, **2020**, 24, 355-377	3.1	9
46	Recent developments and strategies for the discovery of TACE inhibitors. *Expert Opinion on Drug Discovery*, **2020**, 15, 779-801	6.2	7
45	Novel Multitarget Directed Triazinoindole Derivatives as Anti-Alzheimer Agents. *ACS Chemical Neuroscience*, **2019**, 10, 3635-3661	5.7	20
44	New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents. *Scientific Reports*, **2018**, 8, 1650	4.9	7
43	Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review. *Mini-Reviews in Medicinal Chemistry*, **2018**, 18, 1332-1353	3.2	8
42	Computational Modelling of Kinase Inhibitors as Anti-Alzheimer Agents. *Neuromethods*, **2018**, 347-417	0.4	1
41	Gemini Amphiphile-Based Lipoplexes for Efficient Gene Delivery: Synthesis, Formulation Development, Characterization, Gene Transfection, and Biodistribution Studies. *ACS Omega*, **2018**, 3, 11802-11816	3.9	6
40	Drug-fortified liposomes as carriers for sustained release of NSAIDs: The concept and its validation in the animal model for the treatment of arthritis. *European Journal of Pharmaceutical Sciences*, **2018**, 125, 11-22	5.1	5
39	Vicinal Diaryl Oxadiazoles, Oxazoles, and Isoxazoles **2018**, 277-303		2
38	Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis. *Journal of Medicinal Chemistry*, **2018**, 61, 8563-8593	8.3	51
37	Vicinal Diaryl Triazoles and Tetrazoles **2018**, 191-219		2
36	Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. *Bioorganic Chemistry*, **2017**, 70, 256-266	5.1	27

35	Vicinal diaryl azole-based urea derivatives as potential cholesterol lowering agents acting through inhibition of SOAT enzymes. *European Journal of Medicinal Chemistry*, **2017**, 130, 107-123	6.8	8
34	Contemporary developments in the discovery of selective factor Xa inhibitors: A review. *European Journal of Medicinal Chemistry*, **2016**, 121, 671-698	6.8	28
33	Benzylpiperidine-Linked Diarylthiazoles as Potential Anti-Alzheimer's Agents: Synthesis and Biological Evaluation. *Journal of Medicinal Chemistry*, **2016**, 59, 5823-46	8.3	60
32	Identifying the structural features and diversifying the chemical domain of peripherally acting CB1 receptor antagonists using molecular modeling techniques. *RSC Advances*, **2016**, 6, 1466-1483	3.7	5
31	Exploration of 6,7-dimethoxyquinazoline derivatives as dual acting α1- and AT1-receptor antagonists: synthesis, evaluation, pharmacophore & 3D-QSAR modeling and receptor docking studies. *RSC Advances*, **2016**, 6, 30661-30682	3.7	1
30	One-pot synthesis, biological evaluation, and docking study of new chromeno-annulated thiopyrano[2,3-c]pyrazoles. *Molecular Diversity*, **2016**, 20, 639-57	3.1	5
29	A catalyst- and solvent-free multicomponent synthesis and docking study of some new antiproliferative N5-allyl-quinolylpyrido[2,3-b][1,4]benzodiazepinone precursors. *New Journal of Chemistry*, **2016**, 40, 4931-4939	3.6	6
28	Medicinal Chemistry Perspective of Fused Isoxazole Derivatives. *Current Topics in Medicinal Chemistry*, **2016**, 16, 2863-2883	3	44
27	Development of a credible 3D-QSAR CoMSIA model and docking studies for a series of triazoles and tetrazoles containing 11β-HSD1 inhibitors. *SAR and QSAR in Environmental Research*, **2016**, 27, 265-92	3.5	7
26	Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity. *Molecular Diversity*, **2015**, 19, 871-93	3.1	8
25	A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. *Expert Opinion on Therapeutic Patents*, **2015**, 25, 1093-116	6.8	22
24	Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer. *European Journal of Medicinal Chemistry*, **2015**, 105, 1-38	6.8	44
23	3-Substituted 1-methyl-3-benzazepin-2-ones as 5-HT2C receptor agonists. *RSC Advances*, **2015**, 5, 91908-91921	3.7	1
22	Virtual screening-based identification of lead molecules as selective TACE inhibitors. *Medicinal Chemistry Research*, **2015**, 24, 226-244	2.2	13
21	Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity. *SAR and QSAR in Environmental Research*, **2015**, 26, 905-23	3.5	14
20	Discovery of anti-malarial agents through application of in silico studies. *Combinatorial Chemistry and High Throughput Screening*, **2015**, 18, 151-87	1.3	6
19	Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. *European Journal of Medicinal Chemistry*, **2014**, 79, 298-339	6.8	47
18	Synthesis and biological evaluation of some novel pyrido[1,2-a]pyrimidin-4-ones as antimalarial agents. *European Journal of Medicinal Chemistry*, **2014**, 79, 422-35	6.8	13

17	Three-dimensional quantitative structure–activity relationship CoMFA/CoMSIA on pyrrolidine-based tartrate diamides as TACE inhibitors. *Medicinal Chemistry Research*, **2013**, 22, 4192-4201	2.2	10
16	Synthesis and investigation of anti-inflammatory activity of novel nitric oxide donating hybrid drugs. *Medicinal Chemistry Research*, **2013**, 22, 3510-3517	2.2	3
15	Novel methods and strategies in the discovery of TACE inhibitors. *Expert Opinion on Drug Discovery*, **2013**, 8, 157-81	6.2	21
14	Unequivocal role of pyrazine ring in medicinally important compounds: a review. *Mini-Reviews in Medicinal Chemistry*, **2013**, 13, 1607-25	3.2	57
13	Advances in studies on collagenase inhibitors. *Exs*, **2012**, 103, 83-135		4
12	Determination of structural requirements of influenza neuraminidase type A inhibitors and binding interaction analysis with the active site of A/H1N1 by 3D-QSAR CoMFA and CoMSIA modeling. *MedChemComm*, **2011**, 2, 710	5	15
11	Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE. *European Journal of Medicinal Chemistry*, **2011**, 46, 5549-55	6.8	12
10	Novel TACE inhibitors in drug discovery: a review of patented compounds. *Expert Opinion on Therapeutic Patents*, **2010**, 20, 31-57	6.8	44
9	Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors. *Journal of Computer-Aided Molecular Design*, **2010**, 24, 143-56	4.2	35
8	Development of highly predictive 3D-QSAR CoMSIA models for anthraquinone and acridone derivatives as telomerase inhibitors targeting G-quadruplex DNA telomere. *Journal of Molecular Graphics and Modelling*, **2010**, 29, 229-39	2.8	22
7	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 8418-56	3.4	81
6	Prodrug designing of NSAIDs. *Mini-Reviews in Medicinal Chemistry*, **2009**, 9, 124-39	3.2	44
5	Development of predictive 3D-QSAR CoMFA and CoMSIA models for beta-aminohydroxamic acid-derived tumor necrosis factor-alpha converting enzyme inhibitors. *Chemical Biology and Drug Design*, **2009**, 73, 97-107	2.9	27
4	Current perspective of TACE inhibitors: a review. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 444-59	3.4	102
3	Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: design, synthesis, molecular modeling, and preliminary biological evaluation. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 3604-17	3.4	26
2	Structural investigations of acridine derivatives by CoMFA and CoMSIA reveal novel insight into their structures toward DNA G-quadruplex mediated telomerase inhibition and offer a highly predictive 3D-model for substituted acridines. *Journal of Chemical Information and Modeling*, **2009**,	6.1	25
1	3D-quantitative structure-activity relationship studies on benzothiadiazepine hydroxamates as inhibitors of tumor necrosis factor-alpha converting enzyme. *Chemical Biology and Drug Design*, **2008**, 71, 363-73	2.9	32